# OnCo record paper-klimova-phased-seq-validation-oncotarget-2025 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-klimova-phased-seq-validation-oncotarget-2025/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-klimova-phased-seq-validation-oncotarget-2025" ;
  schema:name "Analytical validation of a circulating tumor DNA assay using PhasED-Seq technology for detecting residual disease in B-cell malignancies"@en ;
  schema:description "The laboratory validation of Foresight's phased-variant blood test in lymphoma, which detected tumour DNA at below one part per million when given plenty of DNA."@en ;
  schema:url <https://onco.cc/key-papers/paper-klimova-phased-seq-validation-oncotarget-2025/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://doi.org/10.18632/oncotarget.28719>, <https://pubmed.ncbi.nlm.nih.gov/40353795/> ;
  schema:sameAs <https://doi.org/10.18632/oncotarget.28719> ;
  schema:datePublished "2025"^^xsd:gYear ;
  schema:author "Klimova N, Close S, Kurtz DM, et al." ;
  onco:cancers <https://onco.cc/cancers/dlbcl/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/> ;
  onco:drugs <https://onco.cc/drugs/foresight-clarity/> ;
  onco:companies <https://onco.cc/companies/foresight-diagnostics/> ;
  onco:terms <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/tumour-informed-assay/> ;
  onco:journals <https://onco.cc/journals/oncotarget/> .